TELA Bio appoints William Plovanic to board; expands board to seven members

TELA Bio, Inc.

Board increased from six to seven members; Plovanic appointed as Class I director through 2026 annual meeting.
Plovanic is Managing Director, Healthcare Equity Research at Canaccord Genuity; also former CEO/CFO of Obalon Therapeutics.
Received initial equity grant: option for 17,550 shares (36-month vest) and RSU for 11,925 shares (3-year vest).
Annual board retainer of $45,000; will receive annual equity awards starting at 2026 meeting (11,700 options + 7,950 RSUs).
Plovanic is independent under Nasdaq rules; no related party transactions disclosed.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.